PFCS
ACRV icon

Pale Fire Capital SE’s Acrivon Therapeutics ACRV Stock Holding History

Pale Fire Capital SE’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,235
Closed -$91.7K – 64
2024
Q4 		$91.7K Buy
+15,235
New +$111K 0.02% 45

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pale Fire Capital SE's ACRV Position: Q1 2025 in Review

Pale Fire Capital SE sold out of Acrivon Therapeutics (ACRV) in Q1 2025, closing a stake of 15,235 shares — an estimated $91.7K sold.

Pale Fire Capital SE first reported a position in ACRV in Q4 2024 and held it in 1 quarter. The position peaked at $91.7K in Q4 2024. 63 funds tracked by Wall St. Rank hold ACRV as of Q1 2025.

  • Pale Fire Capital SE reported no remaining Acrivon Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Pale Fire Capital SE sold 15,235 Acrivon Therapeutics shares in Q1 2025, an estimated $91.7K.
  • Pale Fire Capital SE first reported a position in Acrivon Therapeutics in Q4 2024 and held it in 1 quarter.
  • Pale Fire Capital SE's Acrivon Therapeutics position peaked at $91.7K in Q4 2024.
  • 63 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2025.

Based on Pale Fire Capital SE's 13F filing for Q1 2025, filed 14 May 2025.